Viyash Life Sciences said it intended to seek further investment opportunities to build scale after establishing an integrated generic pharmaceutical platform in India in partnership with the private equity giant Carlyle.
Private equity giant Carlyle has partnered with active pharmaceutical ingredients and bulk drugs manufacturer Viyash Life Sciences to build an integrated generic pharmaceutical platform in Viyash’s local market, India, alongside the company’s founder and co-founder.
Viyash was established by the former Mylan chief operating officer Hari Babu in February 2019, with co-founder Srihari Raju Kalidindi joining in August of that year
The Belgian value-added medicines specialist company struck two commercialization deals over its novel valacyclovir oral suspension that span three continents, marking a further milestone in the product’s development.
A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.
Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.
Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.
As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.
Viatris continues to make progress on remediation at the firm’s stricken manufacturing facility in Indore, India, following a warning letter and import alert delivered at the tail end of 2024.
A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.
